Kamyar Afarinkia

London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure-activity relationships, and therapeutic perspectives.

Single versus dual EGFR/PARP inhibition: Mechanistic rationale, synthetic approaches, pharmacophoric features, structure-activity relationships, and therapeutic perspectives.

Journal: European journal of medicinal chemistry

Published: May 01, 2026

Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies.

Beyond PARP-HDAC inhibition: mechanistic rationale and medicinal chemistry insights from single to shared-target strategies.

Journal: Bioorganic chemistry

Published: March 10, 2026

InhibitWin duo: Rational design and structural insights into dual PARP/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation.

InhibitWin duo: Rational design and structural insights into dual PARP/HDAC inhibitors for synergistic DNA repair disruption and epigenetic modulation.

Journal: European journal of medicinal chemistry

Published: January 12, 2026

Identification of Benzenesulfonamide-Containing Thiazolidine-2,4-Dione Derivatives as Novel Carbonic Anhydrase II and VII Inhibitors with Anti-Epileptic Activity.

Identification of Benzenesulfonamide-Containing Thiazolidine-2,4-Dione Derivatives as Novel Carbonic Anhydrase II and VII Inhibitors with Anti-Epileptic Activity.

Journal: Journal of medicinal chemistry

Published: December 03, 2025

Clinicopathological analysis of GLUT-1, GLS1, and GLS2 expression in breast cancer tissues from Jordanian patients.

Clinicopathological analysis of GLUT-1, GLS1, and GLS2 expression in breast cancer tissues from Jordanian patients.

Journal: Scientific reports

Published: December 31, 2024

Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.

Journal: Translational oncology

Published: August 22, 2024

Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition.

Synergy trap for guardian angels of DNA: Unraveling the anticancer potential of phthalazinone-thiosemicarbazone hybrids through dual PARP-1 and TOPO-I inhibition.

Journal: Bioorganic chemistry

Published: August 01, 2024

A method for estimation of plasma protein binding using diffusion ordered NMR spectroscopy (DOSY).

A method for estimation of plasma protein binding using diffusion ordered NMR spectroscopy (DOSY).

Journal: RSC medicinal chemistry

Published: April 09, 2024

Niosomal Delivery of Celecoxib and Metformin for Targeted Breast Cancer Treatment.

Niosomal Delivery of Celecoxib and Metformin for Targeted Breast Cancer Treatment.

Journal: Cancers

Published: September 13, 2023

tert-Butyl(2-oxo-2H-pyran-5-yl)carbamate as the First Chameleon Diene Bearing an Electron-Donating Substituent.

tert-Butyl(2-oxo-2H-pyran-5-yl)carbamate as the First Chameleon Diene Bearing an Electron-Donating Substituent.

Journal: Molecules (Basel, Switzerland)

Published: July 18, 2022

Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens.

Development of novel isatin thiazolyl-pyrazoline hybrids as promising antimicrobials in MDR pathogens.

Journal: RSC advances

Published: July 15, 2022

Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms.

Discovery of 2,4-thiazolidinedione-tethered coumarins as novel selective inhibitors for carbonic anhydrase IX and XII isoforms.

Journal: Journal of enzyme inhibition and medicinal chemistry

Published: January 07, 2022

Showing 1-12 of 28

Last Updated: 09/26/2026